CONFERENCE PROGRAM

Current as at 17 October 2022, subject to change.
All program times listed are local Taiwan time.

ACPE 2022
ISPE's 14th
Asian Conference on
Pharmacoepidemiology
Oct. 21-23, 2022

Tainan, Taiwan

Saturday 22 October 2022

07:30-17:00	Registration desk open			
08:30-10:00	**CONFERENCE OPENING AND KEYNOTE PRESENTATION**			
Room:	Lecture Hall 4			
	Opening remarks – **Tobias Gerhard FISPE,** President, International Society for Pharmacoepidemiology			
	Welcome - Yea-Huei Kao Yang FISPE, Chair, ACPE Local Host Committee			
	Welcome - ACPE Scientific Steering Committee **Soko Setoguchi FISPE,** Conference Chair			
	Keynote Speech **Pharmacoepidemiology for the future in Asia/Pacific and around the globe** Soko Setoguchi FISPE, Rutgers University, USA			
10:00-10:30	**MORNING BREAK / POSTER VIEWING**			
10:30-12:00	**CONCURRENT SYMPOSIA SESSION**			
	SYMPOSIUM 1. Environmental Pharmacoepidemiology around the world: Climate change, medications, and health outcomes	**SYMPOSIUM 2. Training of young Pharmacoepidemiologists in Asia-Pacific regions: Challenges and future potentials**	**SYMPOSIUM 3. Adequate for comparison? Global perspectives on external comparator studies in rare diseases**	**SYMPOSIUM 4. Pregnancy studies using Real-world Data from Asia and Europe: Fit-for-data considerations demonstrated with case examples**
Room:	Lecture Hall 3	Lecture Hall 4	Lecture Hall 1	Lecture Hall 2
Moderators:	**Debra Rowett,** University of South Australia, Australia **Yea-Huei Kao FISPE,** National Cheng Kung University, Taiwan	**Edward Lai,** National Cheng Kung University, Taiwan **Daniel Tsai, Alice Su, Nai-Yu Chen and Steven Shen,** National Cheng Kung University, Taiwan student chapter	**Joan Largent,** IQVIA, USA	**Ju-Young Shin,** Sungkyunkwan University, South Korea
Speakers:	**Climate change, health and Pharmacoepidemiology** Soko Setoguchi FISPE, Rutgers University, USA **Climate data in Asia** Chuan-Yao Lin, Academia Sinica, Taiwan **Air pollution-medications interactions and adverse health outcomes: A case study within Taiwan** Shu Ping Huang, National Cheng Kung University, Taiwan **Cyclone disruption of healthcare and associated health outcomes: A case for cancer therapies** Benjamin Bates, Rutgers University, USA	**Tobias Gerhard FISPE,** President, International Society for Pharmacoepidemiology **Sebastian Jugl,** University of Florida, USA and College of Pharmacy, Germany **Miyuki Hsing-Chun Hsieh,** National Cheng Kung University, Taiwan **Nathorn (Nui) Chaiyakunapruk,** University of Utah College of Pharmacy, USA; Thailand **Nicole Pratt,** Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia **Swu-Jane Lin,** University of Illinois, Chicago, USA; Taiwan	**Nao Takano,** Pharmaceuticals and Medical Devices Agency, Japan **Cathy Lerro,** Oncology Center of Excellence's (OCE) Real World Evidence Program, Food and Drug Administration (FDA), USA **K. Arnold Chan FISPE,** National Taiwan University Research Center, Taiwan **Mehmet Burcu,** Merck & Co Inc, USA **Gerd Rippin,** IQVIA, Germany	**Han Eol Jeong,** Sungkyunkwan University, South Korea **Kenneth KC Man,** University College London, UK and The University of Hong Kong, Hong Kong **Mette Bliddal,** University of Southern Denmark, Denmark **Hedvig Marie Egeland Nordeng,** University of Oslo and University of Oslo, Norway **Shih-Chieh Shao,** Keelung Chang Gung Memorial Hospital, Taiwan **Esther WY Chan,** University of Hong Kong, Hong Kong

12:00-13:30	**LUNCH** **12:15 SPOTLIGHT POSTER SESSION 1 (IN-PERSON PRESENTERS)**
Room:	1F Corridor Poster Area
Chairs:	**Nicole Pratt**, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia **Maggie Weng**, National Cheng-Kung University Medical Center, Taiwan
	F.2 Comparison of standard-dose with reduced-dose of non-vitamin k antagonist oral anticoagulant in atrial fibrillation patients by risk of bleeding Wei-Siang Ciou, National Taiwan University, Taiwan
	F.13 First-line therapies in recurrent or metastatic head and neck cancer: A systematic review and network meta-analysis Szu-Han Hu, Kaohsiung Medical University, Taiwan
	C.23 Background incidence rates of adverse events of special interest for COVID-19 vaccines in Taiwan: A nationwide cohort study Chih-Wan Lin, Taiwan Drug Relief Foundation, Taiwan
	N.30 The correlation between exposure of antibiotics in early childhood and risk of autism spectrum disorder and attention-deficit/hyperactivity disorder Kai-Lin Yang, National Taiwan University, Taiwan
	C.3 Maternal use of benzodiazepine receptor agonists and risk of neurodevelopmental disorders in offspring: A population-based study in Taiwan Yi lin Chiang, National Defense Medical Center, Taiwan
	A.8 Effectiveness of pharmaceutical care in patients with chronic kidney disease: Evidence from a tertiary hospital in Taiwan Yen-Hao Liao, Linkou Chang Gung Memorial Hospital, Taiwan
	J.3 Real-world effectiveness of follow-up care on the reduction of suicidal attempts in patients with opioid use disorder Cheng-Chan Shih, National Cheng Kung University, Taiwan

13:30-15:00	**CONCURRENT CONTRIBUTED PAPER SESSION**					
	Moms, babies and vulnerable persons	**Be careful for the elderly**	**Global safety information of COVID vaccine (I)**	**Cancer treatment and cancer risks**	**Improving health care delivery**	**Vaccination and health care policy**
Room:	Lecture Hall 1	Lecture Hall 3	Room 602	Lecture Hall 4	Lecture Hall 2	Room 601
Chairs:	**Krishna Undela,** NIPER Guwahati, India **Ching-Lan Cheng,** National Cheng Kung University, Taiwan	**Sallie Pearson,** School of Population Health, UNSW Sydney, Australia **Fei-Yuan Sharon Hsiao,** National Taiwan University, Taiwan	**Wen-Wen Chen,** Taiwan Drug Relief Foundation, Taiwan **Shirley Li,** University of Hong Kong, Hong Kong	**Sawaeng Watcharathanakij,** Ubon Ratchathani University, Thailand **Yi-Hsin Yang,** National Institute of Cancer Research, Taiwan	**Kenneth Man,** UCL School of Pharmacy, UK **Fang-Ju (Irene) Lin,** National Taiwan University Hospital, Taiwan	**Kiyoshi Kubota,** NPO Drug Safety Research Unit, Japan **Yaa-Hui Dong,** National Yang-Ming University School of Pharmaceutical Science, Taiwan
13:30-13:45	**RISING STAR AWARD RECIPIENT** **1000. Prenatal and infant exposure to acid-suppressive medications and allergic diseases in children: A nationwide cohort study with sibling-matched analysis** Yunha Noh, Sungkyunkwan University, South Korea	**1006. Comparative risk of femur fracture in older adults initiating suvorexant versus z-drugs: Results from the LIFE study in Japan** Motohiko Adomi, Harvard T.H. Chan School of Public Health, USA	**1012. Comparative safety of SARS-COV-2 Vaccination in pediatric population: Using WHO international database** Donghyuk Kim, Sungkyunkwan University, South Korea	**1018. Comparative effectiveness of Nucleos(t)ide Analogues-based treatments for Hepatitis B Virus-related Hepatocellular Carcinoma after curative therapies: Systematic review and network meta-analysis** Yu-Han Huang, Kaohsiung Medical University, Taiwan	**1024. Inequalities in the availability of global core 14 essential drugs in health care facilities of 7 low- and middle-income countries** Shariful Hakim, Shahjalal University of Science and Technology, Bangladesh	**1030. Impact of the universal seasonal influenza vaccination policy in Manitoba, Canada: A population-based, province-wide record-linkage study** George Okoli, University of Manitoba, Canada

	Moms, babies and vulnerable persons	Be careful for the elderly	Global safety information of COVID vaccine (I)	Cancer treatment and cancer risks	Improving health care delivery	Vaccination and health care policy
13:45-14:00	**1001.** Association between prenatal exposure to sedatives and preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder Adrienne Chan, University of Groningen, Hong Kong	**1007.** Real-world use of and adherence to anti-diabetic medications in older patients in Japan; the Shizuoka Study Hiraku Kumamaru, The University of Tokyo, Japan	**1013. Safety of COVID-19 vaccines in pregnancy: A vigibase analysis** Dayeon Kang, Sungkyunkwan University, South Korea	**1019.** Fanconi syndrome associated with anticancer drugs: A disproportionality analysis in a spontaneous reporting database Rifa Shareen, Manipal Academy of Higher Education, India	**1025.** Nationwide Longitudinal Observational Study (2015-2019) for Long-Term Polypharmacy Reduction by National Database focusing on policies and guidelines in Japan Takehiro Ishida, Teikyo University Graduate School, Japan	**1031.** Risk of Idiopathic Thrombocytopenic Purpura (ITP) and thrombocytopenia after influenza vaccination in elderly: A Self-Controlled Case Series (SCCS) study Hee-Jin Kim, Ewha Womans University, South Korea
14:00-14:15	**1002.** Levothyroxine treatment among pregnant woman and risk of seizure/epilepsy in children: A population-based cohort study Grace Mengqin Ge, The University of Hong Kong, Hong Kong	**1008.** Reduction of potentially inappropriate medications using PIM-Taiwan criteria in elderlies in long-term care facilities in the northern area of Taiwan Yen-Ju Hsieh, National Yang Ming Chiao Tung University, Taiwan	**1014.** Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry Yoshinori Takeuchi, Toho University, Japan	**1020.** Myelodysplastic syndrome transformation associated with the use of antineoplastic agents: A disproportionality analysis in a spontaneous reporting database Amulya Bhatkal, Manipal Academy of Higher Education, India	**1026.** Impact of the National Tuberculosis Control Program in South Korea using a Nationwide Database: An interrupted time series analysis In-Sun Oh, SungKyunKwan University, South Korea	**1032.** Burden of pneumococcal disease in adults – A retrospective database study in Hong Kong Qiuyan Yu, The University of Hong Kong, Hong Kong
14:15-14:30	**1003.** The Influence of COVID-19 pandemic on the utilization pattern of childhood vaccines in a South Indian community Merrin Mathew, JSS Academy of Higher Education and Research, India	**1009.** Anticholinergic burden and risk of acute cardiovascular events in elderly patients: A population-based case crossover study Wei-Ching Huang, National Cheng Kung University, Taiwan	**1015.** Adverse events following COVID-19 vaccines: An active surveillance study Juny Sebastian, JSS Academy of Higher Education and Research, India	**1021.** Palbociclib and Ribociclib use in stage IV breast cancer females: A comparative retrospective observational study Mohamed Izham Mohamed Ibrahim, Qatar University, Qatar	**1027.** Professionals' and patients' perspective on role of community pharmacists in pharmacovigilance and patient counselling Irina Kazaryan, Yerevan State Medical University, Armenia	**1033.** Human Papillomavirus Vaccine (HPV): India has a knowledge gap? Sheba Baby John, JSS Academy of Higher Education and Research, India
14:30-14:45	**1004.** Systematic comparison of drug information resources for recommendations on drug use in pregnancy Atiqulla Shariff, JSS Academy of Higher Education and Research, India	**1010.** Benign prostatic hyperplasia medication and the risk of delirium: A population-based self-controlled case series Sheng-Yung Chang, National Cheng Kung University, Taiwan	**1016.** COVID-19 vaccine-induced interstitial lung disease in WHO pharmacovigilance database: Case/non-case study Min-Taek Lee, Chung-Ang University, South Korea	**1022.** Drug-repositioning of beta-blockers for bladder cancer: A disproportionality inverse signal analysis in spontaneous reporting database Lipin Lukose, Manipal Academy of Higher Education, India	**1028.** Incorporating telepharmacy into COVID-19 patient care could improve patients with their drug related problems: A preliminary study Rujira Panya, Dokkhamtai Hospital, Thailand	**1034.** Impact of changing reimbursement criteria on Anti-VEGF treatment patterns among wAMD patients: An interrupted time series analysis Lin-Chieh Meng, National Taiwan University, Taiwan
14:45-15:00	**1005.** Beta-blockers reducing acute exacerbation of COPD among COPD with AF patients: Evaluation in different severity of COPD ShanJu Lin, National Cheng Kung University, Taiwan	**1011.** The risk of prostatic hyperplasia with concomitant use of warfarin and statin: A population-based cohort study Hehyun Won, Ewha Womans University, South Korea	**1017.** Immune-related adverse events after COVID-19 vaccination among patients with autoimmune diseases using World Health Organization VigiBase Seohyun Kim, Sungkyunkwan University, South Korea	**1023.** Carvedilol and risk of cancer in patients with heart failure Chengsheng Ju, UCL School of Pharmacy, UK	**1029.** Interventions and outcomes related to pharmacist services for people infected with COVID-19: A systematic review Ali Ahmed, Monash University, Pakistan	**1035.** Real-World treatment patterns for atopic dermatitis in South Korea: a nationwide claims database analysis Ahhyung Choi, Sungkyunkwan University, South Korea
15:00-15:30	**AFTERNOON BREAK / POSTER VIEWING**					

15:30-17:00	CONCURRENT SYMPOSIA SESSION			
	SYMPOSIUM 5. Use of Real-World Data in drug repurposing	**SYMPOSIUM 6: The evolving landscape of biosimilars in the world: Barriers to uptake and priorities for real-world evidence generation**	**SYMPOSIUM 7. RWD/RWE application in regulatory and reimbursement decision makings**	**SYMPOSIUM 8. Drug safety and effectiveness in Asians: what is the same and what isn't compared with non-Asians with cardiovascular drugs/outcomes?**
Room:	Lecture Hall 4	Lecture Hall 3	Lecture Hall 2	Lecture Hall 1
Moderators:	**Edward Lai,** National Cheng Kung University, Taiwan **Darren Toh,** Harvard University, USA	**Nicole Pratt,** Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia	**Bor-Sheng Ko,** President, Taiwan Society of Pharmaco-economics and Outcome Research; National Taiwan University Cancer Center, Taiwan **Fei-Yuan Sharon Hsiao,** National Taiwan University, Taiwan	**Kiyoshi Kubota FISPE,** NPO Drug Safety Research Unit Japan, Japan **K. Arnold Chan FISPE,** National Taiwan University, Taiwan
Speakers:	**Overview of the symposium** Edward Lai, National Cheng Kung University, Taiwan **Potential and challenges of using real-world data for drug repurposing** Jenni Ilomaki, Monash University, Australia **Hypothesis generation by mechanism action of drug – pharmacotherapy perspective** Wallis Lau, UCL School of Pharmacy, UK **Hypothesis generation by chemical structure approach - pharmaceutical chemistry perspective** Hsin-Yi Hung, National Cheng Kung University, Taiwan **Hypothesis generation by using data driven approach – statistical and pharmacoepidemiology perspective** Nicole Pratt, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia **Hypothesis generation by "Eight Principles of Diagnosis" (八綱論證) - pharmacognosy & traditional Chinese medicine perspective** Sio-Hong Lam, National Cheng Kung University, Taiwan **Using electric health records: SGLT2 inhibitors and ophthalmologic diseases** Shih-Chieh Shao, National Cheng Kung University, Taiwan **Using claim databases: SGLT2 inhibitors and respiratory diseases** Ju-Young Shin, Sungkyunkwan University, Korea	**Nicole Pratt,** Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Australia **Shirley Xue LI,** The University of Hong Kong, Hong Kong **Debra Rowett,** Southern Adelaide Local Health Network, Australia **Ylenia Ingrasciotta,** The University of Messina, Italy	**How pharmaceutical industry cane meet the real-world data request from regulatory and reimbursement bodies?** Belle Chou, Global Integrated Access Strategy Lead, Amgen Inc. **RWD/RWE application in regulatory and reimbursement decision making in Japan** Isao Kamae, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan **RWD/RWE application in regulatory and reimbursement decision making in Korean** SeungJin Bae, College of Pharmacy, Ewha Womans University, Seoul, Korea	**K. Arnold Chan FISPE,** National Taiwan University, Taiwan **Kiyoshi Kubota FISPE,** NPO Drug Safety Research Unit Japan, Japan **Esther WY Chan,** University of Hong Kong, Hong Kong **Chern-En Chiang,** Taipei Veterans General Hospital, Taiwan
18:30-20:30	GALA DINNER (This is a ticketed event booked during the registration process) **Venue:** B1, East+West Gate, Shangri-La Far Eastern, Tainan 89, Section West, University Road, Tainan City			

CONFERENCE PROGRAM

Current as at 13 October 2022, subject to change. All program times listed are local Taiwan time.

Sunday 23 October 2022

07:30-17:00	**Registration desk open**
08:00-08:55	**STUDENT BREAKFAST SESSION** Co-hosted by the ISPE student council and the NCKU student chapter
Room:	Room 604
Facilitator:	**Miyuki (Hsing-Chun) Hsieh**, ISPE Student Chair
	This is a social event designed for students and young investigators to meet new friends and learn how they can involve more in ISPE! Attended students will be divided into small groups to participate in ice-breaking activities and some fun games! No registration is required and 50 serves of local Southern Taiwan breakfast will be prepared for free in the first come, first served manner.

09:00-10:00	**CONCURRENT HOT TOPIC SESSION**	
Room:	Lecture Hall 4	Lecture Hall 3
Chairs:	**Edward Lai,** National Cheng Kung University, Taiwan	**Sheng-Feng Sung**, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Taiwan
	TOPIC 1: Clinical application of applying machine learning to determine empirical antibiotics treatment in bloodstream infections Yingfen Hsia, Queen's University Belfast, Belfast	**TOPIC 2: Predicting colorectal cancer survival from whole slide images using deep Learning** Sun-Yuan Hsieh, National Cheng Kung University, Tainan

10:00-10:30	**MORNING BREAK / POSTER VIEWING**

10:30-12:00	**CONCURRENT CONTRIBUTED PAPER SESSION**					
	Pysch or neuro	**Risks in lipid control**	**Global safety information of COVID vaccine (II)**	**Risks with sugar**	**Looking for safety signals**	**All about kidneys**
Room:	Lecture Hall 1	Lecture Hall 3	Room 602	Lecture Hall 4	Room 601	Lecture Hall 2
Chairs:	**Frank May**, FISPE, Australia **Kun-Pin Hsieh**, Kaohsiung Medical University, Taiwan	**Meng-Ting Wang**, National Yang Ming Chiao Tung University, Taiwan **Chui Sze Ling (Celine),** The University of Hong Kong, Hong Kong	**Benjamin Bates**, Rutgers University, USA **K. Arnold Chan** FISPE, National Taiwan University Research Center, Taiwan	**Shiro Tanaka**, Kyoto University, Japan **Huang-tz (Anita) Ou**, National Cheng Kung University, Taiwan	**Hiraku Kumamaru**, University of Tokyo, Japan **Chi-Chuan Wang**, National Taiwan University, Taiwan	**Kai-Li Liaw**, Merck, USA **Chung-Yu Chen**, Kaohsiung Medical University Hospital, Taiwan
10:30-10:45	**2000. Gabapentin misuse, abuse, suicide, dependence and behavior related adverse event reports: Data mining within the FDA adverse events reporting system (FAERS)** Hanya Aboulnaga, Alsalam Port Said General Hospital, Egypt	**2006. Evaluation of statin exposure and influenza vaccination on risk of rhabdomyolysis: A case-centered analysis** Che-Yu Chen, National Cheng Kung University, Taiwan	**2012. Incidence of SARS-CoV-2 reinfection in Malaysia by vaccine types (BNT162b2, CoronaVac, and AZD1222) and risk exposure levels** Teh Hoon Shien, National Institute of Health, Malaysia	**2018. Long-term clinical outcomes of oral antidiabetic drugs as fixed-dose combinations: A nationwide retrospective cohort study** Sangjun Cho, Sungkyunkwan University, South Korea	**2024. A new system for drug safety signal detection and triage integrating prescription sequence symmetry analysis and tree-based scan statistics** Miyuki Hsing-Chun Hsieh, National Cheng Kung University, Taiwan	**2030. Risk of acute kidney injury associated with dapagliflozin compared with DPP-4 inhibitors: A propensity-matched cohort study** Hui-Eon Lee, Ewha Womans University, South Korea
10:45-11:00	**2001. The suicide risk of augmentation therapy in patients with treatment-resistant depression – a population-based cohort study** Daniel Hsiang-Te Tsai, National Cheng Kung University, Taiwan	**2007. PCSK9 inhibitors and infection-related adverse events: A pharmacovigilance study using the World Health Organization VigiBase** DaHyun Park, Sungkyunkwan University, South Korea	**RISING STAR AWARD RECIPIENT** **2013. Myocarditis and pericarditis after mRNA COVID-19 vaccination in Taiwan from June 2021 to May 2022** Chih-Wan Lin, Taiwan Drug Relief Foundation, Taiwan	**2019. Clinical impacts of frailty on patients with diabetes mellitus considering the age of onset and drugs of choice** Shih-Tsung Huang, National Taiwan University, Taiwan	**2025. Identifying predictors of adverse drug reactions: Where machine learning fails** Stephanie Long, McGill University, Canada	**2031. Association between use of non-steroidal anti-inflammatory drugs and the risk of end-stage renal disease: A nested case-control study** Yu-Huan Shih, National Cheng Kung University, Taiwan

	Pysch or neuro	Risks in lipid control	Global safety information of COVID vaccine (II)	Risks with sugar	Looking for safety signals	All about kidneys
11:00-11:15	2002. The risk assessments of suicide attempts and suicide for asthma patients using Montelukast: A retrospective cohort study Te-Jung Kung, National Yang Ming Chiao Tung University, Taiwan	2008. Trajectories of low-density lipoprotein cholesterol and incident cardiovascular disease risk in patients with chronic kidney disease Shih-Wei Wang, Kaohsiung Chang Gung Memorial Hospital, Taiwan	2014. The Association between COVID-19 vaccine and acute myocardial infarction in Korean nationwide study Na-Young Jeong, Ewha Womans University, South Korea	2020. Adaptation of risk equations for cardiovascular diseases in the Taiwanese type 2 diabetes population: Adoption, validation, and recalibration Kah-Suan Chong, National Cheng Kung University, Taiwan	2026. Analysis and signal mining on 1177 reports of adverse drug reactions related to antibacterial-induced coagulopathy An Fu, Medical school of Chinese PLA, China	2032. Exit-site infection and subsequent risk of peritoneal dialysis-related peritonitis: Self-controlled case series analysis Surapon Nochaiwong, Chiang Mai University, Thailand
11:15-11:30	2003. Association of long-acting injectable and oral antipsychotics with hospitalizations for substance use in people with schizophrenia and comorbid substance use Yue Wei, The University of Hong Kong, China	2009. Prevalence and prescription trend of metabolic syndrome in the United States: Analysis of National Health and Nutrition Examination Survey 2007-2018 Ning Wei Huang, Taipei Medical University, Taiwan	2015. The risk of acute transverse myelitis following COVID-19 vaccination in Korean population-based study Eunsun Lim, Ewha Womans University, South Korea	2021. Association of non-alcoholic fatty liver disease risk with GLP-1RAs and SGLT2is in type 2 diabetes: A nested case-control study Kaicheng Chang, Chang Gung Memorial Hospital, Taiwan	2027. Predicting antibiotic-resistance in hospitalised patients using machine learning models with epidemiological data Ha Nguyen, University of Medicine and Pharmacy, Viet Nam	2033. Polymorphisms of the CYP3A5 gene and their impact on tacrolimus dosage and trough concentration among kidney transplant patients Yen-Lin Chang, Taichung Veterans General Hospital, Taiwan
11:30-11:45	2004. Association between risk of neurodegenerative diseases and combined antiretroviral therapies in patients with HIV infection Hye-Min Park, Sungkyunkwan University, South Korea	2010. Optimal timing of non-vitamin K antagonist oral anticoagulants after intracranial hemorrhage in atrial fibrillation patients: A sequential trial emulation study Yu-Han Wu, National Taiwan University, Taiwan	2016. Risk of arrhythmia after mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A self-controlled case series study Min Fan, The University of Hong Kong, Hong Kong	2022. Cardiovascular events of incretin mimetics and SGLT-2 Inhibitors as an add-on to metformin monotherapy: A systematic review and network meta-analysis Krishna Undela, National Institute of Pharmaceutical Education and Research, India	2028. Validity of claims-based algorithm to identify venous thromboembolism in Japan Haoqian Chen, Rutgers State University of New Jersey, USA	2034. Risk of vascular events under the treatments with Janus kinase inhibitors in rheumatoid arthritis patients using Japanese health insurance database Ryoko Sakai, Meiji Pharmaceutical University, Japan
11:45-12:00	2005. Effectiveness and safety of continuous use of low-molecular-weight heparin versus switching to Non-vitamin-K antagonists in patients with cancer-associated venous thromboembolism Wei Kang, The university of Hong Kong, Hong Kong	2011. Association between direct oral anticoagulants discontinuation and coding-based frailty after minor bleeding in patients with atrial fibrillation: The Shizuoka Study Shiori Nishimura, Shizuoka Graduate University of Public Health, Japan	2017. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: A population-based study of 2.3 million vaccine recipients Xi Xiong, The University of Hong Kong, Hong Kong	2023. Newer class of antidiabetic drugs and bladder cancer: A pharmacovigilance-based drug-repurposing in FAERS database Subeesh Viswam, Manipal Academy of Higher Education, India	2029. Overcoming real-world data limitations in creating external control arms for randomized clinical trials Mengfei Wu, ZS Associates, USA; CK Wang, COTA	2035. The risk of fracture after denosumab discontinuation in osteoporosis patients: A nationwide cohort study Yu Hsuan Kuo, Taipei Medical University, Taiwan

12:00-13:30	**LUNCH** **12:15 SPOTLIGHT POSTER SESSION 2 (ON-LINE PRESENTERS)**
Room:	Lecture Hall 4
Chairs:	Ju-Young Shin, Sungkyunkwan University, Korea Li-Ting Kao, National Defense Medical Center, Taiwan
	C.6 Effectiveness and safety of fixed-dose combination of inhaled corticosteroid and long-acting beta agonist in treatment of bronchiectasis Ting-Lin Ding, National Yang Ming Chiao Tung University, Taiwan
	F.7 Perioperative brain protection of dexmedetomidine in children with congenital heart disease: A meta-analysis Jian Gong, Shenyang Pharmaceutical University, China
	C.12 A quantitative bias analysis on oral non-vitamin k antagonist anticoagulants and risk of gastrointestinal bleeding using real-world data Yein Jeon, Johns Hopkins University, USA
	C.15 Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the Food and Drug Administration adverse event database Ashwin Kamath, Manipal Academy of Higher Education, India
	A.15 Seeing eye-to-eye on real-world evidence: Is guidance from Japan and China consistent with recommendations from REALISE in Asia? Yan Ran Wee, Costello Medical, Singapore
	N.17 Economic evaluation of riluzole treatment in amyotrophic lateral sclerosis: A systematic review Thaiphat Rattana-Amonloet, Chiang Mai University, Thailand
13:30-15:00	**AsPEN SYMPOSIUM: Rising Investigator Asian-Pacific Regions**
Room:	Lecture Hall 4
	The AsPEN symposium will highlight the missions, achievements and strategies of the AsPEN and will also showcase presentations from three groups of young researchers who have collaborated on cross-country projects in Pharmacoepidemiology. These young researchers are competing for a new award, the AsPEN Rising Investigator, Asian-Pacific Regions which will be judged during the symposium. **Introduction of AsPEN: the missions, achievements and strategies of AsPEN** Nam-Kyong Choi, Ehwa Women's University Korea, Korea **Group presentations** **Group 1:** Han Eol Jeong, Eunsun Lim, Steven Shen, Jun Ni Ho, Zixuan Wang Mentors: Nam-Kyong Choi and Nicole Pratt **Group 2:** Juliana de Oliveira Costa, Na-Young Jeong, Sungho Bea, Miyuki Hsieh, Jack Janetzki, Adrienne Chan Mentors: Kenneth Man and Ju-Young Shin **Group 3:** Hee-Jin Kim, Dongwon Yoon, Daniel Tsai, Claudia Bruno, Shiori Nishimura, Le Gao Mentors: Wallis Lau and Edward Lai **Announcement of winner team and rising investigators & Future directions for the AsPEN** Kenneth KC Man, University College London, UK and The University of Hong Kong, Hong Kong
15:00-15:30	**AFTERNOON BREAK / POSTER VIEWING**
15:30-17:00	**KEYNOTE SESSION**
Room:	Lecture Hall 4
	Real-World Evidence Driven Decision Making in Asian Pacific Regions: Current and Future Perspective. **Moderators:** Darren Toh, Sharon Hsiao and Edward Lai Pharmacoepidemiology perspective: ISPE representative – Sallie Pearson, Australia Pharmacoeconomic perspective: ISPOR representative – Bor-Sheng Ko, Taiwan Pharmacovigilance perspective: ISoP representative – Krishna Undela, India **Panel discussion:** Futuristic approach on the integration of ISPE, ISPOR and ISoP Asian Chapters/SIGs
17:00-17:30	**AWARD PRESENTATIONS and ANNOUNCING ACPE 2023** **CONFERENCE CLOSE**
Room:	Lecture Hall 4
Moderator:	Frank May, FISPE
	Closing remarks **Soko Setoguchi FISPE,** Conference Chair